Form 4 for IBRX ImmunityBio, Inc.
Accepted 2026-07-01 17:04:34 ET · period of report 2026-06-29 · accession 0001849739-26-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-07-01 17:04 | 2026-06-29+ | IBRX | Selecky Christobel | Dir | M - OptEx | $2.94 | +96.7K | 1,000 | New | +$284.4K |
| DMT | 2026-07-01 17:04 | 2026-06-29+ | IBRX | Selecky Christobel | Dir | S - Sale+OE | $9.01 | -96.7K | 0 | -100% | -$871.2K |
| DMT | 2026-07-01 17:04 | 2026-06-29+ | IBRX | Selecky Christobel | Dir | M - OptEx | $0.00 | -96.7K | 124.4K | -44% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | M | A | 32,173 | $2.98 | 32,173 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-29 | M | A | 33,549 | $2.99 | 65,722 | D | — | — | |
| 3 | Common | Common Stock | 2026-06-29 | M | A | 30,000 | $2.84 | 95,722 | D | — | — | |
| 4 | Common | Common Stock | 2026-06-29 | S | D | 95,722 | $9.01 | 0 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. (F2) Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2026-06-30 | M | A | 700 | $2.98 | 700 | D | — | — | |
| 6 | Common | Common Stock | 2026-06-30 | M | A | 300 | $2.99 | 1,000 | D | — | — | |
| 7 | Common | Common Stock | 2026-06-30 | S | D | 1,000 | $9.00 | 0 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. |
| 8 | Derivative | Stock Option (right to buy) | 2026-06-29 | M | D | 32,173 | $0.00 | 35,764 | D | $2.98 · 2023-06-12 to 2032-06-14 | 32,173 Common Stock | |
| 9 | Derivative | Stock Option (right to buy) | 2026-06-29 | M | D | 33,549 | $0.00 | 124,714 | D | $2.99 · 2024-06-10 to 2033-06-13 | 33,549 Common Stock | |
| 10 | Derivative | Stock Option (right to buy) | 2026-06-29 | M | D | 30,000 | $0.00 | 132,786 | D | $2.84 · 2026-06-08 to 2035-06-18 | 30,000 Common Stock | |
| 11 | Derivative | Stock Option (right to buy) | 2026-06-30 | M | D | 700 | $0.00 | 35,064 | D | $2.98 · 2023-06-12 to 2032-06-14 | 700 Common Stock | |
| 12 | Derivative | Stock Option (right to buy) | 2026-06-30 | M | D | 300 | $0.00 | 124,414 | D | $2.99 · 2024-06-10 to 2033-06-13 | 300 Common Stock |